Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Ardelyx, Inc. is next on our list.
TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating. The adjustment followed an update to the firm’s financial model ahead of the ARDX’s fourth-quarter results.
Additionally, on January 27, Jefferies also raised its price target on Ardelyx, Inc. (NASDAQ:ARDX) to $15 from $8 and maintained a Buy rating. The firm highlighted the company as one of the most underrated biotech launches and underlined sustained execution on Ibsrela in 2026, along with potential upside from IBS-C, new CIC indications, and extended intellectual property. Peak sales are now projected at $1.5–$2 billion by 2035, with additional upside if the new 2041 formulation patent proves defendable.
Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company focused on developing and commercializing first‑in‑class gastrointestinal and cardiorenal therapies. Its lead product, tenapanor, treats irritable bowel syndrome with constipation (IBS‑C) and chronic kidney disease‑related conditions.
While we acknowledge the potential of ARDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
Content Original Link:
" target="_blank">
